诺泰生物(688076) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥134,246,184.41, representing a decrease of 19.22% compared to the same period last year [6]. - The net profit attributable to shareholders was ¥16,093,060.08, down 59.45% year-on-year [6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥12,683,992.70, a decline of 66.64% compared to the previous year [6]. - Basic and diluted earnings per share were both ¥0.08, down 68.00% compared to the same period last year [9]. - The total comprehensive income attributable to the parent company for Q1 2022 was CNY 16,093,060.08, compared to CNY 39,689,926.57 in Q1 2021, representing a decrease of approximately 59.5% [37]. - Net profit for Q1 2022 was ¥14,993,326.89, compared to ¥38,375,405.93 in Q1 2021, reflecting a decline of approximately 60.9% [35]. Cash Flow - The net cash flow from operating activities was ¥1,447,560.62, reflecting a significant decrease of 89.88% year-on-year [9]. - Cash inflow from operating activities for Q1 2022 was CNY 144,960,960.65, a decrease of 22% from CNY 185,888,929.87 in Q1 2021 [40]. - Cash outflow from operating activities totaled CNY 143,513,400.03 in Q1 2022, down from CNY 171,582,269.97 in Q1 2021, reflecting a reduction of approximately 16.4% [40]. - Net cash flow from investing activities for Q1 2022 was -CNY 103,399,496.64, compared to a positive CNY 28,323,902.22 in Q1 2021, indicating a significant decline [40]. - Net cash flow from financing activities for Q1 2022 was CNY 64,509,412.91, a turnaround from -CNY 20,277,449.77 in Q1 2021 [42]. Assets and Liabilities - The total assets at the end of the reporting period were ¥2,157,126,665.12, an increase of 1.42% from the end of the previous year [9]. - The total current assets as of March 31, 2022, amounted to ¥1,034,676,358.46, a decrease of approximately 6.3% from ¥1,104,100,894.06 on December 31, 2021 [23]. - The company's total liabilities increased to ¥332,813,613.79 from ¥318,137,446.34, marking an increase of about 4.9% [27]. - The total non-current assets increased to ¥1,122,450,306.66 from ¥1,022,805,046.06, showing a growth of approximately 9.8% [26]. - Short-term borrowings rose significantly to ¥143,854,465.42 from ¥77,274,866.38, marking an increase of approximately 86% [26]. Research and Development - Research and development expenses totaled ¥13,086,316.81, a decrease of 11.33% year-on-year, while R&D expenses accounted for 9.75% of operating revenue, an increase of 0.87 percentage points [9]. - Research and development expenses for Q1 2022 were ¥12,588,533.16, down from ¥14,361,829.57 in Q1 2021, a decrease of about 12.4% [31]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,655 [17]. - Total equity attributable to shareholders rose to ¥1,828,027,053.70 from ¥1,811,382,762.95, an increase of approximately 0.9% [27]. Company Strategy - The company attributed the decline in net profit to decreased sales due to the pandemic and increased sales and management expenses [16]. - The company has not reported any significant new product developments or market expansions during this period [21]. - The company plans to continue focusing on market expansion and new product development to drive future growth [35].